 |
||
|
 |
|
|||
Cefixime
Devices and diagnostics. The company employs more than 55, 000 people and markets its products in more than 130 countries. For more information, please visit abbott . AstraZeneca AstraZeneca is a major international healthcare business engaged in the research, development, manufacture and marketing of prescription pharmaceuticals and the supply of healthcare services. It is one of the world's leading pharmaceutical companies with healthcare sales of over .8 billion and leading positions in sales of gastrointestinal, oncology, cardiovascular, neuroscience and respiratory products. In the United States, AstraZeneca is an .7 billion healthcare business with more than 11, 000 employees. AstraZeneca is listed in the Dow Jones Sustainability Index Global ; as well as the FTSE4Good Index. For more information, please visit astrazeneca . Bristol-Myers Squibb Bristol-Myers Squibb is a global pharmaceutical and related health care products company whose mission is to extend and enhance human life. For more information, please visit bms . GlaxoSmithKline GlaxoSmithKline, one of the world's leading research-based pharmaceutical and healthcare companies, is committed to improving the quality of human life by enabling people to do more, feel better, and live longer. For more information, please visit gsk . Members of the Johnson & Johnson Family of Companies Johnson & Johnson, with approximately 109, 100 employees, is the world's most comprehensive and broadly based manufacturer of health care products, as well as a provider of related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. Johnson & Johnson has more than 200 operating companies, including Ortho-McNeil Pharmaceutical, Inc., and Janssen Pharmaceutica Products, L.P. Its operating companies are in 57 countries, selling products throughout the world. Additional information about Johnson & Johnson is available at jnj . Janssen Pharmaceutica Janssen Pharmaceutica Products, L.P. has a long track record in developing and marketing treatments for central nervous system disorders. Based in Titusville, N.J., its other specialty.
1. 2. O'Neill P, Roberts T. Acute otitis media. Clin Evid 2004; 11: 314327. Search date March 2004. Agency for Healthcare Research and Quality. Management of acute otitis media. Evidence Report Technology Assessment No. 15. AHRQ Publication No. 00-E010. Rockville, Md: Agency for Healthcare Research and Quality; June 2000. Available at: : ahrq.gov clinic epcsums otitisum . Accessed April 22, 2005. Johnson CE, Carlin SA, Super DM, et al. Cfeixime compared with amoxicillin for treatment of acute otitis media. J Pediatr 1991; 119: 117122. Leigh AP, Robinson D, Millar ED. A general practice comparative study of a new third-generation oral cephalosporin, cefixime, with amoxycillin in the treatment of acute paediatric otitis media. Br J Clin Pract 1989; 43: 140143. McLinn SE. Randomized, open label, multicenter trial of cefixime compared with amoxicillin for treatment of acute otitis media with effusion. Pediatr Infect Dis J 1987; 6: 9971001. REFERENCES 1. Brittain, D. C., B. E. Scully, T. Hirose, and H. C. Neu. 1985. The pharmacokinetic and bactericidal characteristics of oral cefixime. Clin. Pharmacol. Ther. 38: 590594. 2. Dan, M., and F. Poch. 1995. Comparison of serum bactericidal activities of newer oral cephalosporins, abstr. A94, p. 18. In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C. 3. Faulkner, R. D., P. Fernandez, G. Lawrence, L. L. Sia, A. J. Falkowski, A. J. Weiss, A. Yacobi, and B. M. Siber. 1988. Absolute bioavailability of cefixime in man. J. Clin. Pharmacol. 28: 700706. 4. Faulkner, R. D., W. Bohaychuk, R. E. Desjardins, Z. M. Look, and J. D. Haynes. 1987. Pharmacokinetics of cefixime after once-a-day and twice-a-day dosing to steady state. J. Clin. Pharmacol. 27: 807812. 5. Goto, S., F. Ikeda, M. Ogawa, S. Myazaki, and Y. Kaneko. 1985. In vitro and and flagyl. ABSTRACT Background Neisseria gonorrhoeae can be transmitted from the mother's genital tract to the newborn during birth and can cause gonococcal ophthalmia neonatorum as well as systemic neonatal infection. It can also cause endometritis and pelvic sepsis in the mother. Objectives The objective of this review was to assess the effects of antibiotic regimens in the treatment of genital infection with gonorrhoea during pregnancy with respect to neonatal and maternal morbidity. Search strategy We searched the Cochrane Pregnancy and Childbirth Group's Trials Register 30 January 2007 ; . Selection criteria Randomized trials of one regimen of antibiotic versus another in pregnant women with culture confirmed genital gonococcal infection. Data collection and analysis Eligibility and trial quality were assessed by one review author. Main results Two trials involving 346 women were included. The only outcome included in these trials was the incidence of 'cure' assessed by bacterial culture. Failure to achieve 'microbiological cure' was similar for each antibiotic regimen: amoxicillin plus probenecid compared with spectinomycin Peto odds ratio Peto OR ; 2.29, 95% confidence interval CI ; 0.74 to 7.08 ; , amoxicillin plus probenecid compared with ceftriaxone Peto OR 2.29, 95% CI 0.74 to 7.08 ; and ceftriaxone compared with cefixime Peto OR 1.22, 95% CI 0.16 to 9.01 ; . Side-effects were uncommon for all the tested regimens. Authors' conclusions The number of women included in each of the comparisons is small and therefore, although no differences were detected between the different antibiotic regimens, the trials were limited in their ability to detect important but modest differences. For women who are allergic to penicillin, this review provides some reassurance that treatment with ceftriaxone or spectinomycin appears to have similar effectiveness in producing microbiological cure. With the phenothiazine drugs. Also, careful be made for pigmentary retinopathy, len and chloramphenicol. An application is made to the Court, usually by a close relative, solicitor or an officer of the local authority. This must be accompanied by details of the individual's family circumstances and financial affairs. The Court also requires medical evidence. This is provided by a registered medical practitioner who completes a medical certificate known as Form CP3, confirming that the patient is incapable, by reason of mental disorder, of managing and administering their property and affairs. The Court, in consultation with the Royal College of Psychiatrists and the British Medical Association, has prepared guidance notes to assist medical practitioners in completing the form. Relatives or the patient, at a formal hearing, where a receiver is usually appointed, can raise objections to the process. Relatives are usually appointed as receiver, but in complex cases, or where there may be a conflict of interest, professional people may be more appropriate. The receiver is accountable to the Court for any decisions that are taken, and is expected to visit the patient and be consulted about significant changes in their care. The Court monitors the performance of receivers. There is power to displace an unsuitable receiver. The Court can revoke the authority if convinced by medical evidence that Court of Protection is no longer required as the patient has regained capacity to manage their own affairs. If the Court requires a specialist opinion about a person's mental capacity, it may instruct one of the Lord Chancellor's Medical Visitors to provide a report. CATALYST; CATALYSTS; CHEMICALS AND ADDITIVES; FITTINGS; MATERIALS FOR REVAMPING OF DESULFURIZATION UNIT TO ISOMERIZATION UNIT.; PUMPS & TURBINES; PUMPS AND SPARE PARTS; ROTATING EQUIPMENT W SPARES; ROTATING EQUIPMENT WITH SPARES, PUMPS, COMPRESSORS & TURBINES; TOILET SOAP; WATER TREATMENT CHEMICALS DETERGENT; PLYWOOD; TEAK PLYWOOD; TOILET SOAP; VEGETABLE GHEE; WHITE PLYWOOD; WHITE WOOD DENTAL MATERIALS & SUPPLIES CONTROL MEASUREMENT & PROTECTIONS SYSTEM; CONTROL PROTECTION & MEASURING SYSTEM; CONTROL PROTECTION & MEASURING SYSTEM; BOILER AUXILIARY SYSTEM; MEDICAL APPLIANCES; MEDICAL EQUIPMENT; MEDICAL EQUIPMENT AND APPLIANCES; SURGICAL SUPPLIES; TRANSMISSION LINES SPARES; TURBINE SYSTEM EQUIPMENT GHEE; VEGETABLE GHEE and bactrim. Cathcart, J. E. Brewer, M. Courtney, G. S. Hughes, and V. K. Sood. 1991. Disposition of [14C]-cefpodoxime proxetil after a single oral dose to normal human volunteers, abstr. 101. 4th Int. Symp. Synthesis Appl. Isotopically Labelled Compounds, 3 to 7 September 1991, Toronto, Ontario, Canada. 8. Guay, D. R. P., R. C. Meatherall, G. K. Harding, and G. R. Brown. 1986. Pharmacokinetics of cefixime CL 284, 635; FK 027 ; in healthy subjects and patients with renal insufficiency. Antimicrob. Agents Chemother. 30: 485-490. 9. Hayashi, I., and K. Ohnuma. 1988. Clinical results of CS-807 on acute exacerbation of chronic bronchitis. Chemotherapy To. Development of Recombinant Platelet derived growth factor BB. Development of high tech biological products such as DNA extraction kits and RNA detection kits. Development and commercialisation of white enzyme and tacrolimus and process changes for the production of lovastatin. Development and commercialisation of bulk drugs such as clomipremine, citalopram, carvidl, clopridogel, pentroxyfine, metoprolol, tramedol HCl, metformin HCl, losartan potassium, oxcarbozogapine, fluticabone, propionate glimpride. Development of vaccines for a number of epidemic endemic diseases, sabininactivated polio vaccine. Development of cost effective processes for the manufacture of dicloxacillin sodium, flucloxacillin sodium and cefixime trihydrate and oxacillin sodium. Development of technology for the production of citalopram, moxifloxacin hydrochloride, lamivudine, sertraline hydrochloride, gabapentin, nelfinavin and valsartan. Development of platform technology for soft gelatin capsules. Development of pankare tablets, sorexil in gel preparation and artin oil, herbal formulations for bed sores, burns, wounds and diabetic ulcers. Development and commercialisation of losartan K and simva ammonia salt. Development and commercialisation of bromazepam, clonazepam, clobazam, flupentixol, oxazepam, zaleplan. Development and commercialisation of technologies for tablets in capsules e.g. Pantop - D pantoprazole + domperi and cefadroxil. Mueller SC, Henkel KO, Neumann J, Hehl EM, Gundlach KK, Drewelow B. Perioperative antibiotic prophylaxis in maxillofacial surgery penetration of clindamycin into various tissues. J Craniomaxillofac surg 1999; 27: 172-6. Muoz JL, Alonso MA, Gutirrez MN. Penicilinas. En: Garca JE, Lpez R, Prieto J, eds. Antimicrobianos en Medicina. Barcelona: Prous Science S.A., 1999: 227-50. Nathwani D, Davey P. Strategies to rationalize sepsis management a review of 4 years experience in Dundee. J Infect 1998; 37 Suppl 1 ; : 10-7. Nathwani D, Tillotson G, Davey P. Sequential antimicrobial therapy: The role of quinolones. J Antimicrob Chemother 1997; 39: 441-6. Nathwani D. Sequential switch therapy for lower respiratory tract infections. A European perspective. Chest 1998; 113: 211S-8. Nightingale CH. Pharmacokinetic considerations in quinolone therapy. Pharmacotherapy 1993; 13 2 Pt 2 ; 34S-8S. Nightingale CH, Gousse GC. Streamlining antibiotic therapy with oral quinolones: A commentary for P&T Committee members. Hosp Formul 1988; 23 Suppl B ; : 32-7. Norrby SR. Pharmacoeconomic studies on antibiotics. Current controversies. Pharmacoeconomics 1994; 5: 274-7. Norvell M. Antibiotic streamlining: Monitoring and compliance. Pharm Pract Manage Q 1996; 16: 41-51. Nuijten MJC, Brorens MJA, Hekster YA, Van der Kuy A, Lockefeer JHM, de Smet PAGM, et al. Reporting format for economic evaluation. Part I: Application to the Dutch Healthcare System. Pharmacoeconomics 1998; 14: 159-63. Office of Technology Assessment USC. Impacts of antibiotic-resistant bacteria. Washington. DC.: Government printing office, 1995. Omidvari K, de Boisblanc BP, Karam G, Nelson S, Haponik E, Summer W. Early transition to oral antibiotic therapy for community-acquired pneumonia: duration of therapy, clinical outcomes, and cost analysis. Respir Med 1998; 92: 1032-9. Paganini HR, Sarkis CM, De Martino mg, Zubizarreta PA, Casimir L, Fernandez C, et al. Oral administration of cefixime to lower risk febrile neutropenic children with cancer. Cancer 2000; 88: 2848-52. Paladino JA, Sperry HE, Backes JM, Gelber JA, Serrianne DJ, Cumbo TJ, et al. Clinical and economic evaluation of oral ciprofloxacin after an abbreviated course of intravenous antibiotics. J Med 1991; 91: 462-70. They were very fond of cefixime availability horses and ceftin.
FIG 1-02 Life moves fast. For people with chronic medical conditions, having quick access to new advanced medications can make the dif ference between joining in and enjoying the fast pace of ever yday life, and watching from the sidelines. Innovative new products, such as Cardizem XL, can help people live life to the fullest. Importantly, the present findings revealed that rat PEPT1 and PEPT2 had different characteristics not only in substrate affinity for native dipeptide but also in recognition of a variety of peptide-like drugs. Various -lactam antibiotics showed the different inhibitory potencies against the glycylsarcosine uptake between rat PEPT1 and PEPT2. Ganapathy et al. 6 ; evaluated the Ki values of cefadroxil aminocephalosporin ; and cyclacillin aminopenicillin ; for glycylsarcosine uptake by Caco-2 cells human adenocarcinoma cell line expressing human PEPT1 ; , SKPT cells rat kidneyderived cell line expressing PEPT2 ; , and HeLa cells transfected transiently with human PEPT1 or PEPT2 cDNA. They suggested the differential recognition of these antibiotics by the two peptide transporters; PEPT1 had a much higher affinity for cyclacillin than for cefadroxil, whereas PEPT2 preferred cefadroxil to cyclacillin. The inhibition patterns for these antibiotics observed by Ganapathy et al. 6 ; agreed with our findings for rat PEPT1 and PEPT2. In addition, it should be emphasized that affinities of aminopenicillins and aminocephalosporins for rat PEPT1 in this study closely correlated with the absorption of these antibiotics from in situ rat small intestinal loops 31 ; . Among oral -lactam antibiotics, there are some cephalosporins without an -amino group, such as ceftibuten, cefixime, and cefdinir. Boll et al. 1 ; reported that -lactam antibiotics without an -amino group appeared not to be transported by rabbit PEPT2; in other words, the -amino group of substrates was required to be recognized by rabbit PEPT2. In contrast, it was demonstrated that ceftibuten uptake by the rat renal brush-border membrane vesicles was mediated via two peptide transport systems 19 ; , probably by PEPT1 and PEPT2. We also reported previously that ceftibuten and cefixime were transported by human PEPT1 in Caco-2 cells 14 ; and by rat PEPT1 expressed in oocytes 23 ; and in transfected cells 30 ; with relatively high affinities. Therefore, it has been controversial as to how PEPT1 and PEPT2 are involved in the renal transport of the cephalosporins without an -amino group. Interestingly, we found in the present study that ceftibuten and cefixime inhibited the glycylsarcosine uptake both via rat PEPT1 and via rat PEPT2, suggesting that both antibiotics were recognized not only by PEPT1 but also by PEPT2. In addition, those drugs were twofold more potent in inhibiting the glycylsarcosine uptake via rat PEPT1 than via rat PEPT2, suggesting that -lactam antibiotics without an -amino group had low affinity for the rat PEPT2. Daniel et al. 3 ; previously reported that increasing the hydrophobicity of the NH2-terminal side chain increased the affinities of aminocephalosporins and aminopenicillins to the renal H oligopeptide cotransporter. Because cyclacillin with a very hydrophobic NH2-terminal side chain showed relatively higher affinities to the PEPT1 and PEPT2 than other -lactams used, the hydrophobicity of the NH2-terminal side chain was suggested to contribute to the interaction of -lactams to the peptide transporters Fig. 5; Table 1 and augmentin. Blood Tests: Another part of the research goal is to look for genetic changes in normal blood cells of patients to see if these are related to how the liver handles irinotecan, or whether you will have diarrhea after getting irinotecan. These tests are done on one small sample of blood one teaspoon, 5 ml ; taken from your central line or port ; on the first day of treatment. Bone Marrow Tests: The final part of the research goal is to identify genetic changes in tumor cells found in the bone marrow to see if these are related to whether your tumor gets bigger or smaller after getting treatment. When the bone marrow aspiration is done before entering on the study, up to two extra teaspoons 10 ml ; of your bone marrow may be sent for special studies to identify these genetic changes. This testing will NOT require an extra bone marrow procedure, but will be done at the time the before study bone marrow test is being done. There is a chart at the end of this form that tells you when all tests and procedures before and during the study need to be done. Treatment Plan: Before chemotherapy starts, you will be given the antibiotic cefixime once a day by mouth for five days. Crfixime can be taken in tablet or liquid form. The purpose of the cefixime is to reduce your chance of getting severe diarrhea. Cefixiime will be given every day during the study. After five days of cefixime, you will start taking temozolomide and irinotecan. Temozolomide comes in capsule form and will be taken by mouth. The capsules may be opened and mixed in pudding or applesauce for patients who can't swallow capsules. You will receive irinotecan in liquid from the hospital pharmacist, who will measure out each daily dose in a separate syringe. Because liquid irinotecan does not taste good by itself, the medicine should be mixed in a small amount of CranGrape juice each day to hide the flavor. If you do not like CranGrape juice, then CranApple or Cranberry juice can be used instead. It is important to only mix the medicine in one of these three juices, because irinotecan may not work as well if it is mixed in other liquids like soda, apple juice, or orange juice. The following administration schedule for temozolomide T ; , irinotecan I ; , and cefixime C ; will be used: Week Day 1 T off 2 3 4 off 3. Cefixime with foodCefixime dispersible tab
Including penicillinase- and ; . Cefixime has been shown to be active in vitro against most strains of the following organisms; however, clinical efficacy has not been established. Gram-positive Organisms and buy flagyl. Diagnostic M0769 - Thermometer Braun Thermoscan 4000 PRO 107.00 Each VAT Inclusive Price 125.73 ; Thermometer Braun Thermoscan 4000 PRO . Professional tympanic ear thermometer ideal for patients and situations that require fast, accurate, non-invasive temperature . more info . M0775 - Diagnostic Magnifying Lamp on trolley base 185.00 Each VAT Inclusive Price 217.38 ; Diagnostic Magnifying Lamp on trolley base. * Diagnostic magnifying lamp, suitable for clinical examination procedures * Classic Mag-lamp design with 22 watts daylight . more info . M0779 - Trolley Base for Magnifying Lamp 70.00 Each VAT Inclusive Price 82.25 ; Trolley Base for Magnifying Lamp . Magnifying Lamp. Heavy duty mobile castor base for use with item M1197 DIMENSIONS: 67x18x20cm - Weight: 12kg . more info . M1037 - Head Torch 15.20 Each VAT Inclusive Price 17.86 ; Head Torch . * Lightweight headlamp for personal use . * Dirigible and focusable light source makes it ideal for night-time use in the field or community . * Provides . more info . M1041 - Babinski Percussor Patella Hammer ; 5.25 Each VAT Inclusive Price 6.17 ; Babinski Percussor Patella Hammer ; . * Much easier to use and much more effective than the Taylor tomahawk hammer, whenever you check reflexes * Our hammer has medium . more info.
Beth, who side effects for cefixime was still a patroness of cats.
This study is embargoed until 4: 00 EDT, Friday, May 13. PLENARY PRESENTATION SATURDAY, MAY 14, 3: 00 EDT LEVEL 2, HALL D2 LATE-BREAKING ABSTRACT Lead Author: Alan B. Sandler, MD Vanderbilt University Medical Center Nashville, TN. Recognition of FP side effects problems and making sure clients are referred to the health facility. Freedom from pressure to use or not use FP, or to use a particular method because the CHW likes it. Key Points In this unit we will cover the following key points: How a woman gets pregnant. Childbearing for PLWHA. FP information and counseling. How to give condoms, pills, and ECP. How to provide FP referrals. Application No. Drug CHRONULAC lactulose ; Oral Solution, 10 grams 15 milliliter ml ; . SODIUM NITROPRUSSIDE Injection, 50 mg vial. THIOPLEX thiotepa ; Injection, 15 mg vial. SUPRAX cefixime ; Tablets, 200 and 400 mg. SUPRAX cefixime ; Powder for Oral Suspension, 100 mg 5 ml. GARAMYCIN gentamycin sulfate ; Topical Cream, 0.1 percent. Applicant Aventis Pharmaceuticals, Inc. Elkins-Sinn, Inc., Two Esterbrook Lane, Cherry Hill, NJ 080034099. Immunex Corp., 51 University St., Seattle, WA 981012936. Lederle Laboratories, P.O. Box 8299, Philadelphia, PA 191018299. Do. Schering Corp., 2000 Galloping Hill Rd., Kenilworth, NJ 07033. A multicentre, open-label, randomized study was performed in 501 out-patients with acute otitis media, aged 636 months, to study the impact of treatment with either cefixime suspension 8 mg kg day bd or co-amoxiclav suspension 80 mg kg day tds for 10 days on nasopharyngeal carriage of Streptococcus pneumoniae and Haemophilus influenzae. Of 426 patients with nasopharyngeal cultures at entry to the trial, end of treatment and at follow-up visit 35 days after inclusion ; , significant changes in carriage of S. pneumoniae were observed. The proportion of penicillin-resistant S. pneumoniae was higher in the samples taken at the end of treatment and follow-up than in those taken at inclusion, while the total number of children with this microorganism was lower. The difference at the end of treatment was greater with co-amoxiclav than with cefixime. For H. influenzae the resistance rate remained steady while the number of children with this microorganism decreased. At followup there was no significant difference between the two groups in terms of nasopharyngeal positive culture for S. pneumoniae or H. influenzae. Despite these differences, successful clinical responses were similar at the end of treatment and at follow-up. Cefixime for kids5.01 4.86 4.75 Protein involved in the integration of lipid signaling pathways with 4.55 4.45 4.4 Vacuole import and degradation; Null mutant is viable but exhibits 4.28 4.26 Glutathione Transferase; glutathione transferase; Null mutant is vi 4 High-affinity hexose transporter; glucose permease; Null mutant is 3.86 anthranilate phosphoribosyl transferase; tryptophan requiring 3.69 CCR4 associated factor; CCR4 transcriptional complex componen 3.58 3.57 3.56 Product of gene unknown 3.54 Alcohol dehydrogenase 3.53 3.52 TATA-binding protein tfIId TFIID subunit; Null mutant is inviable 3.5 antioxidant enzyme that provides protection against oxidation syst 3.46 protein similar to StuA of Aspergillus nidulans; transcription factor 3.42 3.37 iso-1-cytochrome c; Cytochrome c deficiency 3.36 3.33 3.3 Product of gene unknown; tah18-1 mutant is hypersensitive to hyd 3.28 Mitochondrial ribosomal protein MRPL40 YmL40 ribosomal prot 3.27 FK506 binding protein, proline rotamase, rapamycin-binding prote 3.18 homologous to the aldo-keto reductase protein family 3.16 NBP35 encodes an essential evolutionary conserved protein with 3.12 essential for anaphase spindle elongation; spindle midzone compo 3.11 3.1 multicopy suppressor of snf1 mutation; zinc finger protein; Null mu High level of sequence similarity to HXT1 and HXT9 hexose trans 3.06 may play a role in the oxidative stress response; flavohemoglobin; 3.05. Table 3. Antibacterial Drugs from 1981 to 2002 Organized Alphabetically by Generic Name within Source generic name carumonam fosfomycin trometamol isepamicin micronomicin sulfate miokamycin mupirocin netilimicin sulfate RV-11 teicoplanin apalcillin sodium arbekacin aspoxicillin astromycin sulfate azithromycin aztreonam cefbuperazone sodium cefcapene pivoxil cefdinir cefditoren pivoxil cefepime cefetamet pivoxil hydrochloride cefixime cefmenoxime hydrochloride cefminox sodium cefodizime sodium cefonicid sodium cefoperazone sodium ceforanide cefoselis cefotetan disodium cefotiam hydrochloride cefozopran hydrochloride cefpimizole cefpiramide sodium cefpirome sulfate cefpodoxime proxetil cefprozil cefsoludin sodium ceftazidime cefteram pivoxil ceftibuten ceftizoxime sodium ceftriaxone sodium cefuroxime axetil cefuzonam sodium clarithromycin dalfopristin dirithromycin ertapenem sodium erythromycin acistrate flomoxef sodium flurithromycin ethylsuccinate fropenam imipenem cilastatin lenampicillin hydrochloride loracarbef meropenem moxalactam disodium panipenem betamipron quinupristin rifabutin rifamixin rifapentine rifaximin rokitamycin roxithromycin sultamycillin tosylate tazobactam sodium telithromycin temocillin disodium ciprofloxacin enoxacin fleroxacin gatilfloxacin grepafloxacin levofloxacin trade name Amasulin Monuril Isepacin Sagamicin Miocamycin Bactroban Netromicine Zalig Targocid Lumota Habekacin Doyle Fortimicin Sunamed Azactam Tomiporan Flomox Cefzon Meiact Maxipime Globocef Cefspan Tacef Meicelin Neucef Monocid Cefobis Precef Wincef Yamatetan Pansporin Firstcin Ajicef Sepatren Cefrom Banan Cefzil Takesulin Fortam Tomiron Seftem Epocelin Rocephin Zinnat Cosmosin Klaricid Synercid Nortron Invanz Erasis Flumarin Ritro Farom Zienam Varacillin Lorabid Merrem Shiomarin Carbenin Synercid Mycobutin Normix Rifampin Rifacol Ricamycin Rulid Unasyn Tazocillin Ketek Temopen Ciprobay Flumark Quinodis Tequin Vaxor Floxacin year introduced 1988 reference ARMC 24 P112334 ARMC 24 P091082 ARMC 21 ARMC 21 P070366 ARMC 25 ARMC 24 P091130 ARMC 26 ARMC 23 ARMC 21 ARMC 24 ARMC 20 ARMC 21 ARMC 33 ARMC 27 ARMC 30 ARMC 29 ARMC 28 ARMC 23 ARMC 19 ARMC 23 ARMC 26 ARMC 20 P127130 ARMC 20 ARMC 34 ARMC 20 P091106 ARMC 31 ARMC 23 ARMC 21 ARMC 28 ARMC 25 ARMC 28 P091108 ARMC 19 ARMC 23 ARMC 28 P070260 P091136 ARMC 23 ARMC 23 ARMC 26 ARMC 35 ARMC 29 P236885 ARMC 24 ARMC 24 ARMC 33 ARMC 33 ARMC 21 ARMC 23 ARMC 28 ARMC 30 P070301 ARMC 30 ARMC 35 ARMC 28 ARMC 23 ARMC 24 ARMC 21 ARMC 22 ARMC 23 ARMC 23 ARMC 28 DNP 15 ARMC 20 ARMC 22 ARMC 22 ARMC 28 ARMC 35 DNP 11 ARMC 29 page 298 305 329 source N N N. The regulation of prostate specific antigen PSA, KLK3 ; expression by AR has been extensively studied as a model for AR mediated gene activation 4-7 ; . Androgenic induction of PSA is mediated by AR binding to the proximal promoter approximately 170 base pairs from the transcription start site, and to several low-affinity AREs in an enhancer approximately 4000 base pairs upstream 4-6 ; . AREs in both the promoter and enhancer are important for induction after androgen stimulation. AR occupies both the promoter and enhancer regions and recruits transcriptional coactivators including p160 and p300, TATA binding protein, mediator, and RNA polymerase II to form the AR. Journal of American Science, 3 ; , 2007, Aibinu, IE, Peters, RF, Amisu, KO, Adesida, SA, Ojo, MO and Tolu Odugbemi, Multidrug Resistance in E.coli 0157 Strains and the Public Health Implication aetiological agents of diarrhea Aboaba et al., 2006 ; . It was first identified as a cause of illness in 1982 Riley et al., 1983 ; and the infections have now since been reported with increasing frequency Fitzpatrick, 1999 ; . Infection with this Escherichia coli serotype is associated with a spectrum of illnesses including watery diarrhea, bloody diarrhea, and the hemolytic uremic syndrome, a potentially fatal condition characterized by acute renal failure Griffin and Tauxe, 1991 ; . Cattle are the principal reservoir for these organisms. Important sources of infection include consumption of undercooked hamburger and other contaminated food products and direct or indirect contact with infected persons Wilson et al., 1997 ; . It is public health importance as it is readily isolated from human and animal wastes that pollute the environment Smith et al., 2003 ; . While therapeutic management of E.coli 0157 infection vary depending on the type of infection, the usefulness of antimicrobials in treating this Shiga-toxin-producing E.coli 0157 infection remains less clear Griffin, 1995; Thielman and Guerrant, 1999 ; . With the emergence and dissemination of antimicrobial resistance in bacteria which is well documented worldwide, Cohen, 2000 ; . E. coli, an important gastrointestinal flora, known to be capable of accepting and transferring plasmids and which under stress readily transfers those plasmids to other species, is therefore considered an important reservoir of transferable antibiotic resistance Enumeration of Escherichia coli and the Coliform Bacteria, 2002 ; . Hence, active surveillance of the antimicrobial resistant pattern of EHEC E.coli 0157 serotype resident in animals that are resistant to its toxin is of public health importance. This study thus, investigates E.coli 0157 infection in human and apparently healthy animals; and the occurrence of multidrug resistance not only to commonly used antibiotics, but also to the broad spectrum drugs.The production of beta-lactamase enzyme as a mechanism of resistance employed by strains obtained in this study was also investigated. MATERIALS AND METHODS Study population During a six-month period from June to November 2006, 200 human stool specimens submitted to the Medical Microbiology and Parasitology Departments of health institutions involved in this study, were analyzed. A hundred were from adults, age range 17- 78 years while the remaining 100 were from children age range 4 months- 12 years. Seventy-five of the specimens from adults were watery, diarrheac stool out of which 40 were collected from out patients with diarrhea attending the Gastro Intestinal Tract Clinic of the Lagos University Teaching Hospital LUTH ; . Thirty-five of the samples from adult were from patients attending the HIV Clinic of Nigerian Institute for Medical Research NIMR ; . The remaining 25 stool samples collected from adult were non - diarrheac stool and were used as control. Ten of these were collected from healthy individuals attending the diagnostic centre LUTH for routine medical check-up while 15 were from HIV patients non-diarrheac ; attending NIMR HIV clinic. The 100 samples from children included 25 non- diarrheac stool from children attending pediatrics unit of LUTH for ailments other than gastro-enteritis control ; , 15 diarrheac stool, comprising of one bloody diarrhoeac stool and 14 non-bloody diarrhoeac stool ; , from children at pediatrics unit of LUTH, and 60 diarrheac stool from children attending Regina Mundi Children Hospital, Lagos. The diarrheac stool specimens were those submitted to these health institutions for the examination of enteric pathogens. Three hundred and fifty faecal samples were collected from livestock from different parts of Lagos and Ogun state. The animal samples obtained were Cattle 200 ; , pigs 50 ; , chicken 50 ; and sheep 50 ; . Specimen collection Fresh faecal specimen were obtained from human into sterile universal containers while for children, for those whose faecal samples could not be collected, rectal swabs were used. This was immediately inoculated into cold modified Stuart's transport medium and kept on ice during transportation. Faeces from cattle, pigs, sheep and chickens observed defecating were collected in sterile universal bottles and transported to the laboratory within 1 hour of collection for processing and culture. Processing of samples All human faecal samples were cultured within 2 hours of collection on Cefixime Tellurite Sorbitol MacConkey agar CT-SMAC, Oxoid CM 813, UK ; plates and incubated at 370C for 24 hours. All non-sorbitol fermenting isolates were characterized and species identification was carried out using standard diagnostic procedures Farmer, 1999 ; . Control strains used were NCTC 12900 0157: h7-v7 N ; and E. coli ATCC 25922 obtained from the Research laboratory of the Department of Medical. V.A. Schuck, I. Rinas, H. Derendorf In vitro microdialysis of docetaxel 2003 AAPS Annual Meeting, Salt Lake City, October 2003. A. Khunvichai, M. Hirt, M. Karmann, L.Joliff, I. Zdrojewski, K. Rand, H. Derendorf A novel indirect response PK-PD model to characterize the effect of faropenem on Streptococcus pneumoniae and Haemophilus influenzae 2003 AAPS Annual Meeting, Salt Lake City, October 2003. E.L. Schuck, A. Dalhoff, H. Stass, H. Derendorf Modeling the biphasic killing kinetics of quinolones 2003 AAPS Annual Meeting, Salt Lake City, October 2003. H. Derendorf How the lung handles drugs, permeability, metabolism and retention Transatlantic Airway Conference, Lucerne, January 2004. H. Derendorf Pharmacokinetics of antimicrobial agents Antibiotic Therapy and DRGs, Berlin, January 2004. H. Derendorf Pharmacokinetics and pharmacodynamics: Relevance for asthma therapy 45th Congress of the German Society for Pulmunology, Frankfurt, March 2004. H. Derendorf Comparing potencies of inhaled steroids Annual Meeting of the American Academy of Allergy, Asthma and Immunology, San Francisco, March 2004. H. Derendorf Microdialysis as a key technique to evaluate exposure-response relationships in drug development Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics, Miami, March 2004. H. Derendorf Microdialysis as a key technique to evaluate exposure-response relationships in drug development FDA Committee for Advanced Education Workshop, Rockville, March 2004. R. Madabushi, V.A. Bhattaram, E.L. Desoky, H. Derendorf Population pharmacokinetic analysis of digoxin in egyptian pediatric patients: A comparison of three different softwares 6th Annual Conference & Themed Workshop of the East Coast Population Analysis Group, Rockville, April 2004. H. Derendorf Pharmaceutical care and health care politics Konrad Adenauer Society, Langenfeld, April 2004. H. Derendorf The general concepts of pharmacokinetics and pharmacodynamics 14th European Congress of Clinical Microbiology and Infectious Diseases, Prague, May 2004. H. Derendorf Kill-curve analysis 14th European Congress of Clinical Microbiology and Infectious Diseases, Prague, May 2004. H. Derendorf, P. Liu, K. Rand, B. Obermann Pharmacokinetic-pharmacodynamic modelling of activities of cefpodoxime and cefixime based on in vivo tissue concentrations and in vitro kill curves 14th European Congress of Clinical Microbiology and Infectious Diseases, Prague, May 2004. H. Derendorf What is the best marker for inhaled corticosteroid safety? Eastern Allergy Conference, Key Biscayne, May 2004. H. Derendorf Dose selection for anti-infective drugs PharmForum 2004, Memphis, May 2004. Cefixime and cloxacillinCefixome, cefixiem, cefixim, ceefixime, cefiximr, cefiximd, cefisime, cfixime, ecfixime, cegixime, cfeixime, cef8xime, xefixime, cefixume, fefixime, cefixkme, cefizime, cefixim3, cefixije, defixime, ceixime, ceffixime, cefix8me, vefixime, cefuxime, cefixxime, cefixim4, cefjxime, cefxime, cefixike, cetixime, cefiixme, cefixmie, cefixims.Suprax cefixime doctorCefixime with food, cefixime dispersible tab, cefixime generation cephalosporin, cefixime drug dose and cefixime for kids. Cefixime and cloxacillin, suprax cefixime doctor, cefixime with lactic acid bacillus tablets and cefixime nursing considerations or cefixime taste. Cefixime with lactic acid bacillus tabletsCharles darwin genetics, entomology site reference.com, physiatrist indianapolis, insecticidal soap safer and microscopic anatomy and organization of skeletal muscle review sheet 14. Postprandial lipaemia, morphology normal, phrenology flac and lymphedema more for_health_professionals or greek medicine tools.
|
|
|
 |
|
||
|
